Capital Rx Stock

cap-rx.comHealthcare / Healthcare providers & servicesFounded: 2017Funding to Date: $1.82B

Capital Rx is a health technology company built around the mission of changing the way prescription drugs are priced and patients are serviced. Its Clearinghouse Model® is the first ethical framework for drug pricing. Capital Rx's enterprise pharmacy platform, JUDI®, connects every aspect of the pharmacy ecosystem in one platform. This company was founded in 2017 and is headquartered in New York, NY.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Capital Rx, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Capital Rx Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Capital Rx Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/28/2024 Series E $115MM $xx.xx $1.26B Atlantic Health System, Banner Health, Hawai�I Pacific Health, Inova Health System, Lehigh Valley Health Network, Memorial Hermann Health System, Nebraska Medicine, Novant Health, Ochsner Health, Wellspan Health
Price per Share
$xx.xx
Shares Outstanding
16,282,494
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlantic Health System, Banner Health, Hawai�I Pacific Health, Inova Health System, Lehigh Valley Health Network, Memorial Hermann Health System, Nebraska Medicine, Novant Health, Ochsner Health, Wellspan Health
08/10/2023 Series D $72MM $xx.xx $1.02B Memorial Hermann Health System
Price per Share
$xx.xx
Shares Outstanding
12,736,825
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Memorial Hermann Health System
06/13/2022 Series C $106MM $xx.xx $850.03MM B Capital, Edison Partners, General Catalyst, Transformation Capital
Price per Share
$xx.xx
Shares Outstanding
20,909,771
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
B Capital, Edison Partners, General Catalyst, Transformation Capital
02/02/2021 Series B $50MM $xx.xx $251.49MM Edison Partners, Transformation Capital
Price per Share
$xx.xx
Shares Outstanding
28,810,136
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Edison Partners, Transformation Capital
07/19/2019 Series A $16.38MM $xx.xx $79.62MM Edison Partners, Emerald Development Managers
Price per Share
$xx.xx
Shares Outstanding
21,399,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Edison Partners, Emerald Development Managers
03/01/2018 Series Seed $3MM $xx.xx $15MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
15,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Capital Rx Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Anthony Loiacono
Co-Founder, Chief Executive Officer & Board Member
Ari Fischel
Chief Financial Officer
Joseph Alexander
Co-Founder, Chief Operating Officer, Chief Strategy Officer & Board Member
Ryan Kelly
Co-Founder, Chief Technology Officer & Board Member
Lloyd Fiorini JD
Chief Compliance Officer and General Counsel

Board

Jared Kesselheim MD
Transformation Capital
Lenard Marcus
Edison Partners
Robert Mittendorff MD
Board Member
Kevin Hill
Board Member

Capital Rx stock FAQs

plusminus

Can you buy Capital Rx stock?

As Capital Rx is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Capital Rx, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Capital Rx stock?

To invest in a private company like Capital Rx through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Capital Rx stock?

Yes, you may sell the Capital Rx stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Capital Rx stock?

If you hold private company shares of Capital Rx – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Capital Rx on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Capital Rx a public company?

No, Capital Rx is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Capital Rx’s stock price?

Capital Rx is a privately held company and therefore does not have a public stock price. However, you may access Capital Rx private market stock price with Forge Data.
plusminus

What is Capital Rx’s stock ticker symbol?

Capital Rx does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Capital Rx News and Media Highlights

Capital Rx nabs $50M backed by Inova, Ochsner and other health system investors

Ten health systems, including Banner Health and Memorial Herman, and digital health equity company Transformation Capital, have invested over $50 million in Capital Rx. This investment will support Capital Rx's cloud-native pharmacy benefits administrator and backend claims processing platform JUDI. The funds will be used for research and development, growth of member and client service teams, and key hiring areas within the company.

Capital Rx Closes on $50 Million from Transformation Capital and Others

New York-based Capital Rx, a pharmacy benefit manager and administrator, has secured over $50 million in a funding round led by Transformation Capital. Other participants included Inova Health System, Atlantic Health System, Banner Health, among others. The funds will be used to lower pharmacy costs, improve patient access, and deliver better outcomes. The firm's total funding now stands at $253 million.

Capital Rx CEO: PBM industry needs to be repaired, not ditched

The CEO of start-up Capital Rx, A.J. Loiacono, argues that the Pharmacy Benefit Managers (PBM) industry needs reform, not elimination. While acknowledging the issues with drug pricing, Loiacono maintains that PBMs perform crucial administrative functions in claims administration and patient management among others. Capital Rx recently became the first PBM serving Medicare, Medicaid, and employer-sponsored health plans to earn a B Corp Certification for social responsibility.
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.